Metixene
Chemical compound
- N04AA03 (WHO)
- 1-methyl-3-(9H-thioxanthen-9-ylmethyl)piperidine
- 4969-02-2
Y
- 4167
- 7232
- DB00340
- 4023
- 32VY6L26ZW
- D08209
- CHEBI:51024
- ChEMBL1201342
- DTXSID1047867
- Interactive image
- CN1CCCC(C1)CC2C3=CC=CC=C3SC4=CC=CC=C24
InChI
- InChI=1S/C20H23NS/c1-21-12-6-7-15(14-21)13-18-16-8-2-4-10-19(16)22-20-11-5-3-9-17(18)20/h2-5,8-11,15,18H,6-7,12-14H2,1H3
- Key:MJFJKKXQDNNUJF-UHFFFAOYSA-N
N
Y (what is this?) (verify)Metixene (brand names Methixart, CholinFall, Tremonil, Trest), also known as methixene, is an anticholinergic used as an antiparkinsonian agent.[2] It has also been reported to induce incomplete autophagy and cell death in metastatic cancer and brain metastases. [3]
See also
References
- ^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
- ^ Morton IK, Hall JM (1999). "Metixene". Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Dordrecht: Springer Netherlands. p. 178. ISBN 978-94-011-4439-1.
- ^ Fares, Jawad (2023). "Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases". Journal of Clinical Investigation. doi:10.1172/JCI161142. PMC 10721147. PMID 37847564. Retrieved 3 November 2023.
- v
- t
- e
| DA precursors | |
|---|---|
| DA receptor agonists |
|
| MAO-B inhibitors | |
| COMT inhibitors | |
| AAAD inhibitors |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
